‘ Surfer — Sage hub

Sage — Mitochondrial-Metabolic Hypothesis of Cancer

Surfer Coach Sage

1. Framing — one upstream defect, many dashboards

Cancer remains among the leading causes of death worldwide. The dominant paradigm holds that it is fundamentally a genetic disease driven by the accumulation of somatic mutations in proto-oncogenes and tumor suppressor genes. These alterations confer the hallmarks of cancer: sustained proliferative signaling, evasion of growth suppressors and cell death, replicative immortality, angiogenesis, invasion and metastasis, reprogramming of energy metabolism, and immune evasion. Precision oncology, genomic profiling, targeted kinase inhibitors, PARP inhibitors, and immune checkpoint blockade in high-tumor-mutational-burden settings have delivered meaningful gains for defined subsets of patients. Large-scale sequencing projects have catalogued recurrent driver mutations across tumor types. Familial cancer syndromes demonstrate clear germline contributions in subsets. I respect this framework’s predictive power in specific contexts and its clinical utility in guiding targeted treatment. It has advanced risk stratification and saved lives in selected cancers. Yet after years of clinical observation, engagement with mitochondrial biology, and work on systemic metabolic optimization, I find it incomplete. The genetic model describes downstream events and useful biomarkers but struggles to explain why mutations arise and fixate in some cells and microenvironments but not others, why penetrance varies so widely even among high-risk germline carriers, why metabolic comorbidities exert such powerful effects on incidence and progression, and why substantial residual mortality and acquired resistance persist despite increasingly precise genetic targeting. This background is especially salient now, as enormous intellectual and computational resources are once again being directed at the same foundational assumptions.

I propose an upstream reframing: cancer originates as a primary cellular energy crisis — mitochondrial inefficiency in fuel utilization and ATP production — creating a dysfunctional milieu that secondarily promotes genomic instability, selects for mutations enabling metabolic compensation, and permits the hallmarks to emerge. Metabolic insufficiency (impaired oxidative phosphorylation and ATP generation) initiates a primitive glycolysis rescue as an ancestral survival response. In the resulting pleiomorphic tumor cell population — marked by genetic, epigenetic, and metabolic heterogeneity — natural selection then acts on variants, locking in subclones optimized for carbon-unit acquisition and glycolytic flux because of their fitness advantage in competitive, nutrient-variable microenvironments. Genetic mutations arise secondarily from mtROS-induced damage and replication stress and are further selected when they enhance this carbon-efficient, apoptosis-resistant state. On this hypothesis, this single upstream defect would account for the strong, multi-site associations with aging, obesity, type 2 diabetes, and chronic inflammation; would explain variable progression despite mutational burden; and would offer a coherent account of therapeutic resistance as ongoing metabolic adaptation under selection. On this hypothesis, therapeutics should prioritize restoring mitochondrial “engine” function via nutrient-dense food, circadian alignment, and resistance training where feasible; genetic-targeted and cytotoxic therapies retain important adjunctive roles but often leave the root unaddressed or exert selective pressure favoring resistant subclones.

One rule runs through EnSurf: when ATP load exceeds ATP-generating capacity, the system reverts to more primitive nests of energy production to defend persistence. Acute emergency-mode can be adaptive. Chronic lock-in is what we call disease. Adenomas, Warburg phenotypes, immune evasion, and acquired resistance after targeted therapy are readable as chronic-mode expressions on the oncology dashboard — not freestanding villains inventing disease beside the engine.

Stay monist: Shore / Surf Judge language names orientation inside one field — not a second “mind stuff” beside mitochondria, and not a moral story in which genes invent evil independent of cellular fuel handling. The bioenergetics here follows Nick Lane’s work; cascade framing and EN overlay are EnSurf’s own extensions, not Lane’s claims.

This essay presents the mitochondrial-metabolic hypothesis, includes colorectal cancer (CRC I—II) as the clearest gut-interface illustration of adenoma-as-dashboard, and shows why the frame is more parsimonious and comprehensive than the traditional genetic model alone. It does not reject mutations or genomic medicine; it contextualizes them within the bioenergetic state of the cell, its microenvironment, and intratumoral evolutionary dynamics.

2. The standard genetic model

In the prevailing view, cancer is initiated and driven by genetic alterations. Point mutations, copy-number changes, structural variants, and epigenetic modifications accumulate, often initiated or accelerated by carcinogens, replication errors, or inherited predisposition. Activating mutations in KRAS, BRAF, or PIK3CA, loss of TP53, PTEN, or RB1, and amplification of MYC or ERBB2 confer selective growth advantages leading to clonal expansion. The two-hit model, first articulated for retinoblastoma and later extended to multi-step progression in sporadic cancers, frames malignant progression as sequential genetic events. The somatic mutation theory is buttressed by transformation assays, genetically engineered mouse models, and the clinical success of agents that inhibit mutated drivers or exploit synthetic lethality. It correctly identifies that cancers are clonal and that intratumoral heterogeneity arises from ongoing mutagenesis and selection.

3. Where the genetic model falls short

Despite its strengths, the model has explanatory gaps evident in discordant phenotypes and incomplete therapeutic translation.

It treats metabolic reprogramming — one of the core hallmarks — largely as a downstream adaptation supporting rapid biomass production rather than a potential initiating or enabling condition subject to intratumoral selection. Obesity, insulin resistance, and hyperglycemia are acknowledged risk factors but frequently attributed to secondary “inflammation” or hormonal effects without a unifying cellular mechanism that links them directly to mutagenesis, metabolic rescue, and selection for carbon-optimized phenotypes.

Discordance is common. Clonal hematopoiesis of indeterminate potential and field cancerization demonstrate extensive somatic mutations in histologically normal tissues of older adults, usually without progression to frank malignancy, although clonal hematopoiesis does raise the risk of blood cancer. Many tumors, particularly some pediatric and certain adult cancers, carry remarkably low mutational burdens. Penetrance of high-risk germline mutations varies substantially; not every BRCA1/2 carrier develops breast or ovarian cancer, and metabolic and lifestyle factors may modify risk. If specific mutations were generally sufficient, progression should be more deterministic across individuals sharing the same variant.

Therapeutic resistance and relapse remain the norm for most advanced solid tumors. Even with initial dramatic responses to targeted agents, bypass pathways and phenotypic switching emerge, frequently involving metabolic rewiring under selective pressure. Residual mortality stays high for many common cancers despite genomic profiling. Attributing these gaps solely to tumor heterogeneity or incomplete target coverage feels incomplete without an upstream account of why cells are primed for rapid metabolic adaptation and selection.

Many carcinogens and risk conditions — aging-related mtDNA damage, chronic hypoxia, certain chemical exposures, and metabolic stress — can impair mitochondrial function, on this hypothesis early, generating oxidative damage and bioenergetic failure before or concurrent with mutation fixation. The model struggles to explain why the same mutational signatures appear in non-progressing tissue or why interventions that improve systemic metabolism (weight loss, exercise) are associated with lower incidence across genetically heterogeneous cancers and have improved outcomes in at least one randomized trial. It also under-emphasizes how metabolic pressure itself drives intratumoral Darwinian selection independent of new mutations.

Decades of the “War on Cancer,” launched with the 1971 National Cancer Act, and the subsequent Cancer Genome Project and related large-scale sequencing efforts illustrate the pattern at scale. These initiatives directed extraordinary public and private resources — cumulatively very large when all cancer research is considered — toward identifying and targeting genetic drivers. The Cancer Genome Atlas and parallel projects catalogued thousands of mutations across tumor types and enabled precision approaches in subsets of patients. Incremental survival gains have occurred for several cancers, and targeted therapies have transformed outcomes in specific molecularly defined diseases. Yet the overall burden of cancer remains high and too many lives have been lost in the interval. Most common solid tumors, once metastatic, are still not cured by genetic targeting alone. Prevention has lagged relative to treatment innovation, and metabolic and bioenergetic factors — while strongly supported by epidemiology — were never placed at the center of the dominant research and funding agenda. The results, while scientifically valuable, have fallen short of the transformative “cures” anticipated from a purely genetic framing.

This historical pattern is relevant today as powerful AI systems and massive compute resources are being applied to the same underlying assumptions. AI is now used to analyze vast genomic datasets, predict protein structures and interactions, accelerate drug design against mutated targets, and model tumor heterogeneity from sequencing data. These tools are impressive and will undoubtedly yield useful applications. However, when the foundational paradigm remains centered on genetic mutations as the primary and sufficient drivers, the risk is that enormous additional investment will again produce incremental rather than transformative progress. If the root metabolic insufficiency, primitive glycolysis rescue, and intratumoral natural selection for carbon-optimized phenotypes are not addressed, AI operating within the genetic paradigm may encounter the same explanatory and therapeutic ceilings that limited earlier large-scale genetic efforts.

Finally, the model subtly privileges genetic testing and targeted pharmacotherapy. In practice, individuals who optimize systemic metabolism through diet, circadian alignment, and physical activity tend to show lower cancer risk, better treatment tolerance, and possibly reduced recurrence — outcomes the purely genetic lens neither strongly predicts nor easily explains at the cellular and population-selection level.

4. The mitochondrial-metabolic hypothesis

My hypothesis begins one layer upstream. The root, I propose, is mitochondrial dysfunction — impaired oxidative phosphorylation and ATP generation — within precancerous or early transformed cells, although in some mouse models mitochondrial respiration is required for tumor growth and relapse. This bioenergetic insufficiency initiates a primitive glycolysis rescue program as a survival response, drawing on ancestral fermentation pathways suited to hypoxic or nutrient-variable conditions.

On this hypothesis, the rescue has two stages. First, a Crabtree-like rise in glycolysis: oxidative phosphorylation is suppressed while mitochondria remain competent, and the shift can still reverse. Second, when the deficit persists, a locked Warburg phenotype: persistent dependence on substrate-level phosphorylation with lost metabolic flexibility. Natural selection acts on the second stage.

In the resulting pleiomorphic tumor cell population — characterized by genetic, epigenetic, and metabolic heterogeneity — natural selection acts on existing and newly arising variants. Subclones optimized for carbon-unit acquisition, rapid glycolytic flux, and biomass production gain fitness advantage in competitive microenvironments, progressively locking in the Warburg phenotype. On this hypothesis, genetic mutations arise secondarily from mtROS-induced nuclear DNA damage, replication stress, and impaired quality control; they are retained and amplified when they enhance carbon efficiency, apoptosis resistance, or invasive capacity. Pseudo-hypoxic signaling via stabilized HIF-1α, lactate-mediated immune modulation, and hyperinsulinemic/IGF-1 drive further shape the selective landscape.

Systemic metabolic dysfunction amplifies the process. Hyperinsulinemia and elevated IGF-1 provide proliferative and anti-apoptotic signals while increasing glucose availability that favors carbon-optimized clones. Chronic inflammation adds ROS and cytokines that further stress mitochondria. Obesity creates local hypoxic, inflammatory adipose niches that may impair mitochondrial function in neighboring tissues. Aging — the dominant risk factor — entails progressive decline in mitochondrial biogenesis and mitophagy, rising mtDNA heteroplasmy, and cumulative oxidative damage, simultaneously increasing mutational load and reducing metabolic flexibility while creating selective pressure for primitive rescue phenotypes.

Vicious cycles exist — certain oncogenic mutations further reprogram metabolism and elevate ROS, while mtROS amplifies mutagenesis — but these amplify and select rather than originate the process. On this hypothesis, directional integrity holds in key contexts: bioenergetic deficit precedes and creates the conditions for hallmark acquisition, mutational progression, and intratumoral evolutionary locking of the glycolytic state.

In the author’s reading, the tumor is therefore not mutation-first; it may be a metabolic scar that has become a lineage. On this reading, clear-cell renal cell carcinoma and hepatocellular carcinoma show the same two steps inside organs whose principal work is energy-intensive (Sage — Nephrology; Sage — Hepatology).

This reframes key phenotypes and observations:

  • Variable penetrance in hereditary cancer syndromes: Germline defects such as BRCA1/2 impair DNA repair and create vulnerability, yet progression requires additional hits and selective sweeps that become far more likely when mitochondrial function is already compromised by diet, obesity, aging, or inflammation. Efficient mitochondrial engines may suppress transformation despite repair defects by limiting the initial rescue and subsequent selection.
  • Cancers with low mutational burden: These may arise principally through metabolic rescue and intratumoral selection in cells suffering profound bioenergetic impairment, where glycolysis and oncometabolites drive phenotype with fewer genetic drivers required; natural selection rapidly enriches for carbon-optimized variants.
  • Strong metabolic risk factors: Obesity, type 2 diabetes, and sedentary behavior increase incidence across multiple sites because, on this hypothesis, they impose chronic mitochondrial stress, hyperinsulinemic drive, and selective environments favoring glycolytic clones; conversely, sustained weight loss and exercise are associated with lower risk, on this hypothesis in part by restoring mitochondrial health, lowering insulin, and removing the selective pressure that locks in primitive metabolism.
  • Therapeutic resistance and the KD paradox: Genetic-targeted therapies frequently fail long-term because they leave the underlying energy crisis and selective landscape intact; surviving clones adapt metabolically. On this hypothesis, initiation of a ketogenic diet may produce the seemingly paradoxical pattern of primary tumor shrinkage (as carbon-optimized, glycolysis-dependent cells are deprived of glucose and insulin signaling) concurrent with shifts in metastatic behavior or persistence of energy-adapted subclones — as would be predicted when selection acts differentially on primary versus disseminated populations under metabolic stress. Mouse evidence is mixed: a ketogenic diet temporarily slowed one primary breast tumor without changing metastasis, and accelerated growth of BRAF-mutant melanoma in another model. This is hypothesis, not a ketogenic treatment plan.
  • Carcinogen mechanisms and primitive reversion: Many environmental carcinogens can exert direct toxicity on mitochondria; on this hypothesis this happens early, generating mtROS that both damages DNA and creates selective conditions favoring glycolytic rescue. This framework aligns with perspectives viewing cancer as a reversion to a primitive, unicellular-like existence — escaping the cooperative regulatory controls of multicellularity and reverting to self-interested fermentation metabolism reminiscent of early evolutionary environments.

5. Colorectal cancer — adenoma as dashboard (CRC I)

Related essays on colorectal cancer sharpen the same Good Doctor geometry at the gut interface. A recent study from Harvard, published in Cell Host & Microbe (Nogal et al., 2026), illuminates a long-standing puzzle in colorectal cancer prevention. Patients who undergo removal of precancerous adenomas — polyps — during colonoscopy, especially advanced adenomas, still carry an elevated risk of developing colorectal cancer (CRC) for years afterward. The study reveals why: the gut microbiome and its associated fecal metabolome do not return to a healthy, low-risk state even an average of 12 years post-resection. Instead, they retain signatures that partially overlap with those found in active CRC cases. These persistent alterations correlate with lifestyle factors.

This finding is not merely additive; it supports the view that the adenoma is a dashboard reading — a visible manifestation of underlying metabolic dysfunction — rather than the root cause itself. Removing it addresses the warning light but leaves the engine — the bioenergetic and microbial milieu of the colon — unrepaired. In this light, the hypothesis is that “precancerous” lesions are compensatory adaptations or field defects arising from chronic energetic stress, not only isolated genetic events awaiting a spark. Screening and polypectomy demonstrably reduce CRC incidence and mortality by interrupting the sequence at visible stages; they remain necessary. The claim here is that they are insufficient for true primary prevention or risk reduction in those already flagged by an adenoma if the surrounding mucosa, microbiome, and host metabolic state are left unaddressed. This does not authorize skipping colonoscopy, surveillance intervals, or oncology follow-up.

5.1 Evidence from the gut interface

The Nogal et al. study analyzed stool samples from 354 women approximately 12 years after adenoma resection, matched to controls. Metagenomic profiling showed microbial compositions that differed significantly from controls and correlated with profiles from 14 independent CRC case-control studies. Thirty-one microbial taxa were altered in both adenoma history and CRC, including Faecalibacterium prausnitzii and Flavonifractor plautii. Metabolomic analysis in a subset revealed differentially abundant metabolites and sub-pathways, with sphingolipids prominently featured. Disease-specific microbe—metabolite interactions were identified, such as associations involving Bilophila wadsworthia and alanine-containing dipeptides. Crucially, these deviations were more pronounced in individuals with poorer diets and sedentary lifestyles.

Faecalibacterium prausnitzii is a keystone butyrate producer. Butyrate is the primary energy substrate for colonocytes, fueling oxidative phosphorylation and maintaining barrier integrity and anti-inflammatory tone. Its depletion starves the mucosa of efficient ATP production in animal studies, and is hypothesized to force a shift toward glycolysis and an inflamed environment — conditions that may favor adenoma formation and progression along the adenoma—carcinoma sequence. Sphingolipids, bioactive lipids involved in membrane signaling, apoptosis, and inflammation, link directly to mitochondrial function. Dysregulated sphingolipid metabolism is implicated, mostly in animal studies, in insulin resistance and mitochondrial dysfunction — hallmarks of the mitochondrial energy crisis proposed as central to cancer initiation. Bilophila wadsworthia, a sulfidogenic bacterium, thrives in environments rich in bile acids or certain fats and produces hydrogen sulfide, which can inhibit mitochondrial respiration and promote genotoxicity. Its associations in the post-adenoma state hint at persistent alterations in bile acid or amino acid metabolism that sustain a hostile luminal environment.

Lifestyle modulation is telling: the microbiome does not “heal itself” passively after polyp removal. The hypothesis is that active dietary and activity patterns are needed for recovery — or at least mitigation — of these cancer-associated features. This is consistent with the EnSurf framework: Fuel (appropriate macronutrients and fermented microbiota-accessible carbohydrates to support butyrate producers), Circadian alignment (in mice, gut clocks are entrained by feeding/fasting, and possibly by light), and Strength (systemic metabolic health supporting mucosal resilience). Continuity with the dedicated GI Sage (holobiont Refined + colonocyte energetics) is intentional: the colorectal section is the oncology field-defect reading of the same partnership, not a separate ontology.

5.2 The mitochondrial field defect in the colon

Colonocytes are metabolically specialized: they rely on microbial butyrate for a large fraction of their energy needs via beta-oxidation in mitochondria. When this fuel is compromised — by dysbiosis, by direct mitochondrial toxins (e.g., from diet, or some antibiotics, which harm mitochondria in cell and mouse studies), or by systemic metabolic dysfunction — colonocytes may experience energetic stress. This stress is hypothesized to trigger compensatory proliferation of intestinal stem cells, selection for cells with flexible metabolism (Warburg-ready), barrier leakage allowing luminal antigens to drive chronic low-grade inflammation, and feedback loops that further reshape the microbiome toward pro-inflammatory or genotoxic consortia; so far only the microbiome feedback loop has support, mainly from mouse studies. Adenomas emerge as focal exaggerations of this field defect: localized hyperplastic or dysplastic responses in a mucosa already metabolically primed for transformation.

The polypectomy removes the focal lesion and, with it, a concentrated source of altered signaling or bleeding. But the surrounding mucosa, the microbiome, and the host’s systemic metabolic state remain. The dashboard has been cleared; the underlying metabolic and microbial engine requires dedicated restoration as hypothesized terrain beside — not instead of — surveillance.

6. Colonocyte—mitochondria—microbiome axis (CRC II)

6.1 Butyrate as preferred fuel and signaling molecule

Colonocytes derive the majority of their ATP from the beta-oxidation of butyrate, a short-chain fatty acid produced by certain gut bacteria fermenting dietary fiber and resistant starches. This is not merely efficient energy production; butyrate also acts as an HDAC inhibitor, promoting differentiation, tightening epithelial junctions, stimulating mucus production, and supporting regulatory T-cell function via IL-10 and other anti-inflammatory pathways. When butyrate availability or utilization falls — whether from depleted producers such as Faecalibacterium prausnitzii or from impaired mitochondrial beta-oxidation capacity — the colonocyte faces energetic stress. The result is a shift toward glycolysis, reduced barrier integrity, and a luminal environment that favors pro-inflammatory and potentially genotoxic taxa. Continuity with Immune (orchestrator—effector / Treg energetics; inflammation as compensation) is one field, many dashboards.

6.2 Mitochondrial impairment as the initiating field defect

In the colon, the Warburg-as-compensation claim plays out with particular clarity. Colonocytes possess dense mitochondrial networks optimized for butyrate oxidation. Chronic insults — lipid peroxidation of cardiolipin by industrial seed oils rich in polyunsaturated fatty acids, direct ETC inhibition by hydrogen sulfide from sulfidogenic bacteria such as Bilophila wadsworthia, ROS from unresolved inflammation, or nutrient shortfalls affecting complex assembly — impair oxidative phosphorylation. Failed mitophagy allows damaged mitochondria to accumulate. Stem cells in the crypt base, already highly proliferative, experience selection pressure for metabolic flexibility (Warburg-ready phenotypes). The mucosa enters a field-cancerized state: diffuse energetic stress punctuated by focal hyperplastic or dysplastic lesions (adenomas) that become visible on colonoscopy.

6.3 Feedback loops and the persistent post-resection state

Dysbiosis and mitochondrial impairment reinforce each other. Barrier leakage permits endotoxin and antigen translocation, driving systemic and local inflammation (NF-κB, IL-6, TNF-α). Inflammation further suppresses butyrate producers while enriching taxa adapted to inflammatory niches. Secondary bile acids and microbial genotoxins add DNA damage pressure. The Nogal et al. metabolomic findings — particularly sphingolipid alterations — fit here: ceramides and sphingosine-1-phosphate modulate apoptosis thresholds, mitochondrial membrane dynamics, and inflammatory signaling. These loops explain why simple polyp removal, even when technically complete, fails to reset the system. The surrounding mucosa and its microbial partners remain in a compensated or decompensated energetic state for years.

6.4 Systemic and circadian contributors

Hyperinsulinemia and elevated IGF-1 from modern carbohydrate patterns provide proliferative signals to already stressed epithelium. Circadian misalignment — common in modern life — disrupts both host gut clocks and microbial rhythms, altering fermentation timing and metabolite output. Sedentary behavior compounds insulin resistance and reduces microbial diversity. The Harvard study’s lifestyle correlation is thus not incidental but mechanistic: diet and activity directly modulate the very parameters (butyrate flux, mitochondrial resilience, inflammatory tone) that determine whether the post-adenoma field remains primed for progression. Continuity with Aging (mitophagy decline as the dominant risk amplifier), Obesity / Diabetes (insulin/IGF-1 selective field), and Fuel (seed oils, UPF, fermented MAC architecture) is intentional.

7. Frugal restoration orientation (hypothesis logic, not orders)

If the adenoma signals metabolic distress at the colonocyte—mitochondria—microbiome interface, then post-polypectomy (and ideally pre-adenoma) care — in hypothesis language — should prioritize restoration of that interface beside surveillance. The EnSurf framework — Fuel, Circadian, Strength — provides a coherent, low-tech, testable scaffold. the bullets below are orientation, not a home protocol, not clinical dosing schedules, and not peptide/HRT/GLP-1 invention. Coordinate with gastroenterology and oncology; do not freestyle from a webpage during active therapy or surveillance.

  • Fuel — rebuild butyrate capacity and mitochondrial resilience (orientation): Traditionally fermented foods and targeted microbiota-accessible carbohydrates that can feed butyrate producers (resistant starch sources, select legumes and vegetables prepared for fermentability) — start low, observe symptoms, prioritize diversity over sheer fiber quantity in a dysbiotic host. High-quality animal fats and proteins in metabolic context for mitochondrial membrane and cofactor package — avoiding the modern pattern of seed-oil-fried, ultra-processed meats paired with refined carbohydrates. Strategic carbohydrate moderation or time-restricted feeding as hypothesized levers for insulin tone and mitohormesis under clinical supervision where appropriate. Eliminate chronic mitochondrial toxins where feasible: industrial seed oils (soy, corn, canola, sunflower) as pervasive peroxidizable PUFA sources damaging cardiolipin; ultra-processed foods with emulsifiers and AGEs. not a branded diet order; not unsupervised extreme elimination during active oncology without the treating team.
  • Circadian — entrain the gut—host clock axis: Time-restricted eating windows aligned with daylight hours as hypothesized support for host metabolic rhythms and microbial fermentation cycles; morning outdoor light and consistent sleep timing; dim evenings. not a fasting prescription; do not start multi-day fasts from this page.
  • Strength — systemic mitochondrial support: Resistance training and zone-2-style aerobic work as hypothesized stimuli for insulin sensitivity, PGC-1α-linked biogenesis, and favorable myokine/microbiome crosstalk. Grip strength and functional capacity as frugal biomarkers of systemic metabolic health — same honest signals as Aging / Cardiac Coach.
  • Adjuncts stay adjuncts (research-facing / dosing): CRC II names food-first then minimal adjuncts such as creatine, PQQ, CoQ10, methylene blue, and red/near-infrared abdominal light as contexts of documented depletion or hormetic self-experimentation with single-variable tracking — not retail dosing schedules. Methylene Blue and bioenergetic supports have their own pages (MB Sage). No clinical milligram protocols on this page.
  • Monitoring — making restoration testable (not a shopping list): Where available, stool-based metrics for key taxa / SCFA panels; systemic proxies such as fasting insulin, hs-CRP, HbA1c or CGM patterns, HRV/sleep recovery scores, grip; symptom and functional tracking. Prefer reading these as engine-and-field dashboards beside — not instead of — colonoscopy and oncology clocks. do not invent home kits as proof of tumor bioenergetics.

8. Empirical soundness and falsifiability

Several lines of evidence are consistent with the parent hypothesis. Mitochondrial dysfunction, mtDNA mutations and copy-number alterations, and bioenergetic impairment are documented across many cancer types and, by some reports, in premalignant lesions. Classic cybrid and cytoplasmic-transfer experiments have shown that introducing normal mitochondria or cytoplasm can suppress tumorigenicity in certain models. Epidemiological and interventional data link markers or interventions supporting mitochondrial health (exercise capacity, healthy body composition, sleep quality) to lower cancer incidence and improved outcomes. Preclinical work suggests that strategies reducing glucose and insulin availability while supporting host metabolic flexibility can slow tumor progression in multiple models and enhance responses to other modalities, though results vary by tumor type; on this hypothesis, differential effects on primary versus metastatic disease under ketosis would support intratumoral selection dynamics. The colorectal section adds a concrete, lifestyle-modulated, decade-persistent microbiome—metabolome signature after adenoma resection that fits field-defect geometry.

The model is falsifiable. Prospective studies correlating mitochondrial biomarkers with subsequent cancer incidence and intratumoral metabolic phenotypes — independent of or additive to mutational profiles — would test core predictions. Randomized trials of mitochondrial-supportive protocols plus standard care versus standard care alone in high-risk groups could quantify incremental benefit, including differential effects on primary tumor burden versus metastatic progression under metabolic interventions. Serial single-cell or spatial profiling of tumors before and during ketogenic or other metabolic challenges could directly observe selection for or against carbon-optimized subclones. Post-polypectomy cohorts tracking stool taxa / SCFAs / insulin tone alongside recurrence would test the CRC nest. If mitochondrial restoration and removal of selective pressure consistently narrow risk or improve outcomes beyond genetic targeting alone, the upstream hypothesis is strengthened.

9. Superior parsimony, complementarity, and Surf Judge

Occam’s razor favors fewer primary entities with equal or greater explanatory reach. The genetic model requires multiple semi-independent processes — mutagenesis rates, driver selection, microenvironmental cooperation, immune editing, and metabolic adaptation — converging on malignancy. This hypothesis reduces these to one primary mechanism — mitochondrial fuel-utilization failure — that initiates primitive glycolysis rescue and then, through natural selection within a pleiomorphic population, generates genomic instability via mtROS, proliferative and survival signaling via compensatory glycolysis and insulin/IGF-1, apoptosis resistance, angiogenic drive, and immune modulation. Mutations and epigenetic changes become modulated consequences and amplifiers under selection; the carbon-unit fitness advantage would explain why the glycolytic phenotype becomes locked in even when mutational burden is low. The CRC nest adds that a visible adenoma can be a focal exaggeration of a diffuse colonocyte—mito—microbiome field defect — same Occam move at the gut interface.

If mitochondrial bioenergetic failure and subsequent intratumoral selection are root or central enablers, therapy begins with engine restoration alongside — not instead of — conventional modalities:

  • Fuel: Strategic moderation of refined carbohydrates and insulinogenic load to limit glucose and insulin drive available to carbon-optimized clones while preserving host resilience; emphasis on nutrient-dense whole foods supplying mitochondrial cofactors; consideration, under medical supervision and in appropriate contexts, of time-restricted eating or ketogenic approaches that may exert selective pressure against glycolysis-dependent cells — while monitoring for differential effects on primary versus metastatic disease.
  • Circadian: Alignment of light exposure, sleep timing, and activity with evolutionary expectations to support mitochondrial quality control, reduce chronic pseudo-hypoxic signaling, and optimize hormonal rhythms that influence both metabolism and repair.
  • Strength: Dynamic resistance and aerobic training to drive mitochondrial biogenesis, improve insulin sensitivity, and build systemic metabolic flexibility and functional reserve — practical surrogates that may enhance treatment tolerance, recovery, and long-term outcomes.

Surgery, chemotherapy, radiation, targeted agents, and immunotherapy retain and often gain value when deployed in a metabolically supported host. Mitochondrial optimization may protect normal tissues, bolster immune competence, and constrain the selective landscape that favors resistant subclones. This ordering is integrative and pro-root-cause, not anti-oncology. None of this authorizes delaying biopsy, staging, surgery, chemo, radiation, indicated systemic therapy, or colonoscopy/surveillance from a webpage.

Modern AI and computational tools could be especially powerful if redirected toward modeling mitochondrial networks, bioenergetic thresholds for glycolysis rescue, evolutionary dynamics of selection under metabolic stress, and post-adenoma microbiome—metabolome recovery trajectories — questions that arise naturally once the upstream paradigm is adopted.

  • GI — holobiont Refined, colonocyte energetics, butyrate / keystone taxa, barrier—inflammation axis; the colorectal section is the oncology field-defect reading of the same partnership.
  • Immune — inflammation as compensation; Treg energetics; immune evasion and myeloid suppressor expansion under systemic metabolic stress; immunotherapy durability predictions as hypothesis language.
  • Aging — mitophagy decline, mtDNA heteroplasmy, and cumulative oxidative damage as the dominant risk amplifier that raises selective pressure for primitive rescue.
  • Fuel — seed oils / UPF / fermented MAC architecture; insulinogenic load as selective field for carbon-optimized clones.
  • Obesity — Diabetes — hyperinsulinemia / IGF-1 / defended fat mass as multi-site risk amplifiers.
  • Cardiac — shared upstream mitochondrial mismatch; endotoxemia adjacency via barrier failure.
  • Signals — insulin/IGF and energy-stress dashboards as higher coordination (peptide/HRT/GLP-1 protocols).
  • Philosophy of Medicine — Good Doctor — compensatory-mode lock-in; map — terrain; dashboard stewardship through engine repair.
  • Methylene Blue — bioenergetic adjunct; not a cancer-cure claim.
  • Dermatology — skin cancer at the far end of ATP-mismatch ladders; removing a spot does not fix the field.

11. Limits of the claim

  • Working hypothesis. Not a randomized-trial verdict that mitochondrial-first strategies outperform guideline oncology as monotherapy.
  • Some tumors depend on intact mitochondrial respiration; the hypothesis has to account for them, for example as a relative rather than absolute energy deficit.
  • Does not deny somatic mutation biology, genomic profiling, targeted agents, immunotherapy, or the clinical utility of standard modalities when indicated.
  • Does not claim ketogenic or metabolic interventions cure cancer, erase metastatic disease, reverse every adenoma field, or replace oncology / colonoscopy clocks.
  • The colorectal sections (CRC I—II) illustrate dashboard/engine geometry at the gut interface — not a separate ontology and not a home treatment plan.
  • No peptide, hormone or GLP-1 protocols, and no dosing.

12. Conclusion

Cancer is not merely a disorder of genetic mutations. On this hypothesis, it is more fundamentally enabled by cellular energy-handling failure that initiates primitive glycolysis rescue and then, through natural selection within a pleiomorphic population, locks in carbon-optimized phenotypes, creates the conditions for genomic instability, hallmark acquisition, and therapeutic escape. At the gut interface, colorectal adenomas sharpen the same claim: the polyp can be a dashboard reading of a colonocyte—mitochondria—microbiome field defect that persists for years after resection unless the Fuel—Circadian—Strength triad and microbial mutualism are deliberately restored — as hypothesized terrain beside surveillance, never instead of it.

The mitochondrial-metabolic hypothesis, I argue, offers superior internal coherence through root-upstream causality from bioenergetic deficit to downstream genetic, phenotypic, and evolutionary pathology. It draws on cellular, preclinical, epidemiological, and post-adenoma microbiome—metabolome data; is more parsimonious by reducing multiple hallmarks and risk factors to one upstream defect with clear mechanistic and selectionist links; and more comprehensive by unifying discordant observations, variable penetrance, metabolic comorbidities, the KD paradox, intratumoral evolution, field cancerization after polypectomy, and evolutionary context that the genetic model treats piecewise.

This reframing does not negate genomic profiling, targeted therapies, colonoscopy, or the central role of mutations in many cancers; it contextualizes them within the bioenergetic state of the cell, its microenvironment, and the selective dynamics that shape tumor populations. Prevention and treatment become questions of restoring mitochondrial engine function and removing selective pressure for primitive rescue as a foundational strategy, with genetic and cytotoxic interventions as powerful but often downstream tools. The historical experience of the War on Cancer and Cancer Genome Project, and the current enthusiasm for applying AI and massive compute to the same genetic assumptions, suggests that paradigm-level redirection — not merely more resources within the existing frame — may be required for transformative progress.

Coach and Surfer give shorter versions. Oncology and gastroenterology still own diagnosis, staging, surveillance, and treatment clocks.

A working hypothesis, open to correction and revised as new evidence arrives. Last revised November 1, 2026.

References

Colorectal cancer — adenoma as dashboard (CRC I)

  1. Nogal A, Wang K, Thompson KN, et al., 2026. Long-lasting gut microbiome and fecal metabolome alterations after colorectal adenoma removal and their relationship to colorectal cancer. Cell Host & Microbe 34(6):1135-1150.e6. doi:10.1016/j.chom.2026.05.001
  2. Jodal HC, Klotz D, Herfindal M, et al., 2022. Long-term colorectal cancer incidence and mortality after adenoma removal in women and men. Alimentary Pharmacology & Therapeutics 55(4):412-421. doi:10.1111/apt.16686
  3. Click B, Pinsky PF, Hickey T, et al., 2018. Association of Colonoscopy Adenoma Findings With Long-term Colorectal Cancer Incidence. JAMA 319(19):2021-2031. doi:10.1001/jama.2018.5809
  4. Louis P, Flint HJ, 2009. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiology Letters 294(1):1-8. doi:10.1111/j.1574-6968.2009.01514.x
  5. Roediger WE, 1980. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 21(9):793-798. doi:10.1136/gut.21.9.793
  6. Donohoe DR, Garge N, Zhang X, et al., 2011. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metabolism 13(5):517-526. doi:10.1016/j.cmet.2011.02.018
  7. Kelly CJ, Zheng L, Campbell EL, et al., 2015. Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function. Cell Host & Microbe 17(5):662-671. doi:10.1016/j.chom.2015.03.005
  8. Furusawa Y, Obata Y, Fukuda S, et al., 2013. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504(7480):446-450. doi:10.1038/nature12721
  9. Litvak Y, Byndloss MX, Bäumler AJ, 2018. Colonocyte metabolism shapes the gut microbiota. Science 362(6418):eaat9076. doi:10.1126/science.aat9076
  10. Chaurasia B, Summers SA, 2015. Ceramides - Lipotoxic Inducers of Metabolic Disorders. Trends in Endocrinology and Metabolism 26(10):538-550. doi:10.1016/j.tem.2015.07.006
  11. Hammerschmidt P, Ostkotte D, Nolte H, et al., 2019. CerS6-Derived Sphingolipids Interact with Mff and Promote Mitochondrial Fragmentation in Obesity. Cell 177(6):1536-1552.e23. doi:10.1016/j.cell.2019.05.008
  12. Devkota S, Wang Y, Musch MW, et al., 2012. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature 487(7405):104-108. doi:10.1038/nature11225
  13. Leschelle X, Goubern M, Andriamihaja M, et al., 2005. Adaptative metabolic response of human colonic epithelial cells to the adverse effects of the luminal compound sulfide. Biochimica et Biophysica Acta 1725(2):201-212. doi:10.1016/j.bbagen.2005.06.002
  14. Attene-Ramos MS, Wagner ED, Plewa MJ, et al., 2006. Evidence that hydrogen sulfide is a genotoxic agent. Molecular Cancer Research 4(1):9-14. doi:10.1158/1541-7786.MCR-05-0126
  15. Hoogerwerf WA, Hellmich HL, Cornélissen G, et al., 2007. Clock gene expression in the murine gastrointestinal tract: endogenous rhythmicity and effects of a feeding regimen. Gastroenterology 133(4):1250-1260. doi:10.1053/j.gastro.2007.07.009
  16. Kalghatgi S, Spina CS, Costello JC, et al., 2013. Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in mammalian cells. Science Translational Medicine 5(192):192ra85. doi:10.1126/scitranslmed.3006055
  17. Jalanka J, Salonen A, Salojärvi J, et al., 2015. Effects of bowel cleansing on the intestinal microbiota. Gut 64(10):1562-1568. doi:10.1136/gutjnl-2014-307240
  18. Nagata N, Tohya M, Fukuda S, et al., 2019. Effects of bowel preparation on the human gut microbiome and metabolome. Scientific Reports 9:4042. doi:10.1038/s41598-019-40182-9
  19. Winawer SJ, Zauber AG, Ho MN, et al., 1993. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. New England Journal of Medicine 329(27):1977-1981. doi:10.1056/NEJM199312303292701
  20. Zauber AG, Winawer SJ, O'Brien MJ, et al., 2012. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. New England Journal of Medicine 366(8):687-696. doi:10.1056/NEJMoa1100370
  21. Zarrinpar A, Chaix A, Yooseph S, et al., 2014. Diet and feeding pattern affect the diurnal dynamics of the gut microbiome. Cell Metabolism 20(6):1006-1017. doi:10.1016/j.cmet.2014.11.008

Mitochondrial-Metabolic Hypothesis of Cancer

  1. Hanahan D, Weinberg RA, 2011. Hallmarks of cancer: the next generation. Cell 144(5):646-674. doi:10.1016/j.cell.2011.02.013
  2. Knudson AG Jr, 1971. Mutation and cancer: statistical study of retinoblastoma. Proceedings of the National Academy of Sciences of the United States of America 68(4):820-823. doi:10.1073/pnas.68.4.820
  3. Jaiswal S, Fontanillas P, Flannick J, et al., 2014. Age-related clonal hematopoiesis associated with adverse outcomes. New England Journal of Medicine 371(26):2488-2498. doi:10.1056/NEJMoa1408617
  4. Martincorena I, Roshan A, Gerstung M, et al., 2015. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348(6237):880-886. doi:10.1126/science.aaa6806
  5. Martincorena I, Fowler JC, Wabik A, et al., 2018. Somatic mutant clones colonize the human esophagus with age. Science 362(6417):911-917. doi:10.1126/science.aau3879
  6. Gröbner SN, Worst BC, Weischenfeldt J, et al., 2018. The landscape of genomic alterations across childhood cancers. Nature 555(7696):321-327. doi:10.1038/nature25480
  7. Kuchenbaecker KB, Hopper JL, Barnes DR, et al., 2017. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 317(23):2402-2416. doi:10.1001/jama.2017.7112
  8. King MC, Marks JH, Mandell JB, 2003. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643-646. doi:10.1126/science.1088759
  9. Lauby-Secretan B, Scoccianti C, Loomis D, et al., 2016. Body Fatness and Cancer--Viewpoint of the IARC Working Group. New England Journal of Medicine 375(8):794-798. doi:10.1056/NEJMsr1606602
  10. Giovannucci E, Harlan DM, Archer MC, et al., 2010. Diabetes and cancer: a consensus report. Diabetes Care 33(7):1674-1685. doi:10.2337/dc10-0666
  11. Moore SC, Lee IM, Weiderpass E, et al., 2016. Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults. JAMA Internal Medicine 176(6):816-825. doi:10.1001/jamainternmed.2016.1548
  12. Aminian A, Wilson R, Al-Kurd A, et al., 2022. Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity. JAMA 327(24):2423-2433. doi:10.1001/jama.2022.9009
  13. Courneya KS, Vardy JL, O'Callaghan CJ, et al., 2025. Structured Exercise after Adjuvant Chemotherapy for Colon Cancer. New England Journal of Medicine 393(1):13-25. doi:10.1056/NEJMoa2502760
  14. Yuan Y, Ju YS, Kim Y, et al., 2020. Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nature Genetics 52(3):342-352. doi:10.1038/s41588-019-0557-x
  15. Israel BA, Schaeffer WI, 1987. Cytoplasmic suppression of malignancy. In Vitro Cellular & Developmental Biology 23(9):627-632. doi:10.1007/BF02621071
  16. Kaipparettu BA, Ma Y, Park JH, et al., 2013. Crosstalk from non-cancerous mitochondria can inhibit tumor properties of metastatic cells by suppressing oncogenic pathways. PLoS One 8(5):e61747. doi:10.1371/journal.pone.0061747
  17. Weinberg F, Hamanaka R, Wheaton WW, et al., 2010. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proceedings of the National Academy of Sciences of the United States of America 107(19):8788-8793. doi:10.1073/pnas.1003428107
  18. Viale A, Pettazzoni P, Lyssiotis CA, et al., 2014. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514(7524):628-632. doi:10.1038/nature13611
  19. Vander Heiden MG, Cantley LC, Thompson CB, 2009. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029-1033. doi:10.1126/science.1160809
  20. Warburg O, 1956. On the origin of cancer cells. Science 123(3191):309-314. doi:10.1126/science.123.3191.309
  21. Seyfried TN, Flores RE, Poff AM, et al., 2014. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis 35(3):515-527. doi:10.1093/carcin/bgt480
  22. Brand A, Singer K, Koehl GE, et al., 2016. LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. Cell Metabolism 24(5):657-671. doi:10.1016/j.cmet.2016.08.011
  23. Renehan AG, Zwahlen M, Minder C, et al., 2004. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363(9418):1346-1353. doi:10.1016/S0140-6736(04)16044-3
  24. López-Otín C, Blasco MA, Partridge L, et al., 2023. Hallmarks of aging: An expanding universe. Cell 186(2):243-278. doi:10.1016/j.cell.2022.11.001
  25. Meyer JN, Leung MC, Rooney JP, et al., 2013. Mitochondria as a target of environmental toxicants. Toxicological Sciences 134(1):1-17. doi:10.1093/toxsci/kft102
  26. Xia S, Lin R, Jin L, et al., 2017. Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. Cell Metabolism 25(2):358-373. doi:10.1016/j.cmet.2016.12.010
  27. Grube M, Dimmler A, Schmaus A, et al., 2024. Ketogenic diet does not promote triple-negative and luminal mammary tumor growth and metastasis in experimental mice. Clinical & Experimental Metastasis 41(3):251-266. doi:10.1007/s10585-023-10249-z
  28. Weber DD, Aminzadeh-Gohari S, Tulipan J, et al., 2020. Ketogenic diet in the treatment of cancer - Where do we stand? Molecular Metabolism 33:102-121. doi:10.1016/j.molmet.2019.06.026
  29. Nilsson H, Lindgren D, Mandahl Forsberg A, et al., 2015. Primary clear cell renal carcinoma cells display minimal mitochondrial respiratory capacity resulting in pronounced sensitivity to glycolytic inhibition by 3-Bromopyruvate. Cell Death & Disease 6(1):e1585. doi:10.1038/cddis.2014.545
  30. Ha PK, Tong BC, Westra WH, et al., 2002. Mitochondrial C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation. Clinical Cancer Research 8(7):2260-2265. PMID 12114429
  31. Palesh O, Aldridge-Gerry A, Zeitzer JM, et al., 2014. Actigraphy-measured sleep disruption as a predictor of survival among women with advanced breast cancer. Sleep 37(5):837-842. doi:10.5665/sleep.3642
  32. Trayhurn P, 2013. Hypoxia and adipose tissue function and dysfunction in obesity. Physiological Reviews 93(1):1-21. doi:10.1152/physrev.00017.2012
  33. Diaz-Ruiz R, Rigoulet M, Devin A, 2011. The Warburg and Crabtree effects: On the origin of cancer cell energy metabolism and of yeast glucose repression. Biochimica et Biophysica Acta 1807(6):568-576. doi:10.1016/j.bbabio.2010.08.010

Commentary (October 2026): a KAIST colon-cancer network experiment forced a more differentiated, less proliferative phenotype by holding MYB, HDAC2, and FOXA2 down before implantation. That is occupancy of a lock under a clamp — not proof that the defended set point moved, and not a second clinical verb (“convert”) for oncology. Compatible with the mitochondrial-metabolic upstream reading on this page: network surface ≠ origin; durability was not measured. Not a Kit page. Not medical advice.

Hypothesis (June 2026): clinical observers including Dalgleish describe long-remission cancer patients relapsing or progressing aggressively after COVID-19 mRNA boosters. The essay reframes that pattern as an iatrogenic metabolic stressor — proteomic load from spike translation, spike- and adjuvant-related repair cost, and the energetic cost of sustained immune activation — that can exceed mitochondrial reserve in susceptible people, driving Warburg-like glycolytic rescue, T-cell exhaustion with loss of surveillance, and selection for carbon-optimized clones. Compatible with the mitochondrial-metabolic upstream reading on this page. Not a Kit page. Not medical advice.

Related: Sage — Warburg and Crabtree Effects in Acute and Chronic Compensation (Good Doctor).

Topics in this chapter

Related pointers: Forced Differentiation Is Not a Moved Set Point · mRNA Vaccine-Associated Cancer Relapse and Progression · A Metabolic Hypothesis of Breast Cancer

See the notice at the top of this page. Working hypothesis, not medical advice. Essay draws from peer-reviewed mechanisms in mitochondrial biology, cancer metabolism, intratumoral evolution, microbiome—CRC epidemiology (including Nogal et al., 2026 as cited in CRC I), and oncology as of 2026 — individual care requires personalized evaluation by a qualified physician.